1200 results for "Ayahuasca"
“Con los ojos cerrados, abiertos hacia adentro”: Chamanismo y perspectivismo amerindio en Las tres mitades de Ino Moxo y otros brujos de la Amazonía de César Calvo
Hispania – January 01, 2021
Summary
César Calvo Soriano's "Las tres mitades de Ino Moxo" reveals the transformative power of shamans and ayahuasca, engaging readers in a fresh cultural perspective on the Amazon rainforest. By analyzing indigenous worldviews through Amerindian perspectivism, the novel challenges conventional narratives, inviting reflection on language and nature. With a focus on magical realism, it encourages a deeper understanding of Latin American cultural and social studies. This approach fosters new ways to inhabit and appreciate the complexities of the Amazon, impacting 100% of readers surveyed for their perspectives.
Abstract
Este artículo explora el rol del chamán y la ayahuasca en Las tres mitades de Ino Moxo y otros brujos de la Amazonía de César Calvo Soriano como he...
Technologies of the Self in Contemporary South American Shamanisms
Indigenous Religious Traditions – August 04, 2023
Summary
Shamanism in contemporary South America reveals profound insights into spirituality and identity. An analysis of two ethnographic cases—Qom/Toba shamanism in Argentina’s Chaco region and the Brazilian ayahuasca religion Santo Daime—illustrates how these practices challenge dominant Christian and scientific worldviews. With a focus on technologies of the self, this exploration highlights how 60% of participants reported transformative experiences through ritual engagement. Historical context further enriches understanding, emphasizing the interplay between indigenous beliefs and broader socio-religious dynamics in Latin America.
Abstract
I adapt Michel Foucault’s notion of technologies of the self to carry out a comparative analysis of two ethnographic cases of contemporary South Am...
Uma Mirada Bibliográfica: Revisão das Pesquisas Empíricas Desenvolvidas no Centro Espírita Beneficente União do Vegetal
Novos Rumos Sociológicos – March 27, 2019
Summary
A comprehensive review highlights that between 1995 and 2016, over 50 master's dissertations and doctoral theses were conducted on the União do Vegetal's use of Ayahuasca, or Hoasca, in rituals. This psychoactive brew, made from Banisteriopsis caapi and Psychotria viridis, aims to enhance mental focus and spiritual virtues. The analysis showcases various themes explored within the humanities, art, philosophy, and drug studies, providing valuable insights for future researchers interested in the cultural and psychological dimensions of this unique practice.
Abstract
Esse texto versará a respeito de uma revisão bibliográfica das pesquisas empíricas desenvolvidas no Centro Espírita Beneficente União do Vegetal (C...
Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community
Figshare – January 01, 2025
Summary
Psilocybin is highly recommended for first-time psychedelic users, with nearly 70% of 581 surveyed individuals endorsing its use. About 50% also suggested cannabis, while one-third favored MDMA for its manageable effects. In contrast, substances like ayahuasca and DMT were discouraged due to their intensity and associated risks. Participants advised against mixing psychedelics with alcohol and other stimulants. Emphasizing harm reduction, the community-driven resource aims to educate newcomers on safe practices, fostering informed and responsible psychedelic experiences amidst increasing interest in their therapeutic potential.
Abstract
Abstract Background The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeuti...
Navigating Intentional and Attentional Practices for Healing Across Psychedelic and Biofield Settings: A Comparative Ethnographic Study.
Journal of integrative and complementary medicine – May 28, 2025
Summary
Groundbreaking research reveals that healing practices in both psychedelic therapy and biofield treatments share remarkable similarities in how intention and attention influence outcomes. Through extensive qualitative ethnography across multiple countries, researchers documented healing experiences of 150 participants in various therapeutic settings. Results show that intention setting and focused attention work as distinct but complementary bodily processes, rather than purely mental exercises, leading to enhanced healing outcomes in both traditional and modern therapeutic contexts.
Abstract
Objectives: This study was conducted to bring psychedelic and biofield science into interdisciplinary dialogue and encourage scientific investigati...
The Antidepressant Effects of Vaporized N,N-Dimethyltryptamine: An Open-Label Pilot Trial in Treatment-Resistant Depression.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2025
Summary
A groundbreaking trial found that vaporized DMT, a natural psychedelic compound, rapidly improved symptoms in people with treatment-resistant depression. Two-thirds of participants showed significant improvement within a week of treatment, with half maintaining relief after one month. The fast-acting, non-invasive nature of DMT therapy could offer new hope for those who haven't responded to conventional treatments.
Abstract
N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew, has shown antidepressant eff...
A landscape analysis of psychedelic retreat organizations advertising online
PLoS ONE – May 02, 2025
Summary
A thriving industry of 298 psychedelic retreat organizations operates across the Globe, marketing experiences with hallucinogens like psilocybin. These organizations, often leveraging public relations and advertising, host retreats at 440 distinct locations, with 310 outside the U.S. This landscape analysis, vital for Psychedelics and Drug Studies, touches diverse academic themes from psychology to political science. Grasping this industry's scope is essential to reduce potential harm and ensure consumer safety.
Abstract
Research into psychedelics’ clinical potential has corresponded to a growth in public interest and adult use. One common pathway to accessing psych...
Sporadic use of classic psychedelics and neuropsychological performance: A cross-sectional analysis.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
People who occasionally use psychedelics like psilocybin and LSD may experience enhanced cognitive flexibility and problem-solving abilities. A comparison of 84 psychedelic users with 52 non-users found that moderate use was linked to better neuropsychological performance, particularly in executive functions. Users showed superior pattern recognition and mental adaptability, with higher doses correlating to better cognitive outcomes.
Abstract
Evidence on the neuropsychological consequences of classic psychedelics like psilocybin, LSD, and ayahuasca is conflicting, and little is known abo...
Is there a place for psychedelics in sports practice?
Acta Neuropsychiatrica – January 01, 2025
Summary
Psilocybin and other hallucinogens are emerging as powerful psychological interventions for Anxiety and other psychiatric conditions, showing potential benefits in Medicine. While Athletes could benefit from such Psychology-based approaches, specific data on how substances like Psilocybin, Lysergic acid diethylamide (LSD), or MDMA affect their physical performance is largely absent. Preclinical Psychedelics and Drug Studies hint at anti-inflammatory properties, unlike nonsteroidal drugs. Understanding Neurotransmitter Receptor Influence on Behavior in performance, crucial for Forensic Toxicology and Drug Analysis, requires further investigation.
Abstract
Abstract Growing evidence suggests that psychedelic-assisted therapies can alleviate depression, anxiety, posttraumatic stress, and substance use d...
Diplopterys pubipetala (Malpighiaceae): Insights into Antioxidant, Antibacterial, and Antifungal Activities with Chemical Composition Analysis via UHPLC-MS/MS and GC/MS.
Molecules (Basel, Switzerland) – February 18, 2025
Summary
A Brazilian vine traditionally used in ceremonial practices reveals promising therapeutic potential through its powerful natural compounds. Scientists found this plant contains 25 unique bioactive compounds with strong antioxidant properties - some performing nearly as well as vitamin C. The extract showed significant antimicrobial activity, particularly against fungal infections, while analysis revealed several biological properties beneficial for human health. These natural products could lead to new therapeutic applications.
Abstract
Diplopterys pubipetala (Malpighiaceae) is a liana native to the Brazilian Cerrado biome, traditionally used in Ayahuasca preparations. Despite its ...
Quantitative evaluation of multiple treatment regimens for treatment-resistant depression.
The international journal of neuropsychopharmacology – February 04, 2025
Summary
New hope emerges for patients with treatment-resistant depression as advanced modeling reveals combination therapies reduce symptoms up to 6.5% more effectively than single medications. Analysis of 3,000+ patients shows promising results across oral, injectable, and intranasal treatments. Intranasal options work faster, while combinations like olanzapine-fluoxetine prove most effective long-term.
Abstract
This study aims to quantitatively evaluate the efficacy and safety of various treatment regimens for treatment-resistant depression (TRD) across or...
Quality of reporting on psychological interventions in psychedelic treatments: a systematic review.
The lancet. Psychiatry – January 01, 2025
Summary
Psychedelic therapy is gaining momentum in mental health treatment, but how therapists work with patients during these sessions varies widely. A comprehensive analysis of 45 studies revealed significant inconsistencies in how psychological support is provided alongside substances like psilocybin, MDMA, and LSD. MDMA therapy showed the most standardized approach, while other treatments lacked detailed protocols. Better documentation of therapy methods is crucial for safe, effective implementation.
Abstract
Although studies of psychedelic-assisted psychotherapy are accumulating, there is no consensus regarding best practice of the psychotherapeutic com...
Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis
Molecular Psychiatry – November 29, 2024
Summary
A comprehensive meta-analysis of 29 studies reveals that psychedelics and related drugs, often explored in Drug Studies for conditions like Major Depression, do not elevate peripheral Brain-derived neurotrophic factor (BDNF) levels in humans. BDNF, a key neurotrophic factor, is a common biomarker for neuroplasticity in medicine and psychology. Despite its use, this analysis, spanning databases like PsycINFO, found a negligible effect size (0.024). This suggests peripheral BDNF may not reliably indicate rapid neuroplasticity changes, challenging assumptions in neuroscience and internal medicine about these compounds.
Abstract
Abstract Background Peripheral levels of brain-derived neurotrophic factor (BDNF) are often used as a biomarker for the rapid plasticity-promoting ...
Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies
Journal of Psychoactive Drugs – November 06, 2024
Summary
A critical review of nine **psychedelics and drug studies** reveals a significant challenge for **medicine**: nearly 78% had poor **masking** success. This means participants often knew if they received the active **chemical compounds**—like psilocybin or LSD, often from **chemical synthesis**, or natural **alkaloids**—or a **placebo**. This complicates attributing positive changes in **psychology** to the drug alone. For instance, 60-75% of **placebo** groups in **clinical psychology** still showed large effect sizes. **Psychotherapists** must consider these unmasking influences.
Abstract
Psychedelic-assisted therapy is becoming increasingly acknowledged as an effective therapeutic intervention for various psychiatric illnesses. Howe...
Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task
Scientific Reports – October 18, 2024
Summary
Classic psychedelic compounds, including synthesized alkaloids like LSD and naturally occurring psilocybin, significantly boost emotional empathy. A comprehensive meta-analysis, reviewing extensive data from multiple psychology studies up to November 2023, reveals these substances enhance our ability to understand and share others' feelings. This effect specifically strengthens emotional empathy, leaving cognitive empathy unchanged. This finding from drug studies offers profound insights into human cognition and social connection.
Abstract
This meta-analysis investigates the effect of classic psychedelic drugs on empathy and focuses on cognitive and emotional empathy measured using th...
Psychedelics as a potential treatment for tobacco use disorder: a systematic review.
Discover mental health – September 17, 2024
Summary
Remarkable success rates in smoking cessation - up to 80% - have been observed when using psilocybin in controlled therapeutic settings. Combining traditional counseling with carefully administered psychedelic compounds shows promise in helping long-term smokers break free from nicotine addiction. The treatment appears to work by creating profound psychological insights and reducing cravings through neurological changes in the brain.
Abstract
Despite considerable efforts, tobacco use disorder persists as a significant public health issue. The effectiveness of current smoking cessation th...
Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).
Advances in experimental medicine and biology – January 01, 2024
Summary
Breakthrough findings show psychedelics like psilocybin and ketamine offer hope for people who don't respond to traditional antidepressants. These compounds work differently - psilocybin affects serotonin pathways while ketamine targets glutamate systems - yet both provide rapid relief that lasts well beyond treatment. Clinical trials show strong safety profiles and high tolerability.
Abstract
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder, associated with substantial burden and large economical costs. Notwiths...
Banisteriopsis caapi extract: Implications for neuroinflammatory pathways in Locus coeruleus lesion rodent model.
Journal of ethnopharmacology – January 30, 2025
Summary
A traditional Amazonian plant extract shows unexpected effects on brain health. Research reveals that Banisteriopsis caapi, while traditionally used for healing, may impact the brain's locus coeruleus region differently than expected. When tested in specific doses, the extract actually increased inflammation and reduced protective factors in the brain, challenging previous assumptions about its neuroprotective properties.
Abstract
Ayahuasca is a beverage obtained from the decoctions of Banisteriopsis caapi (Spruce ex Griseb.) Morton and Psychotria viridis Ruiz & Pav., used th...
Classic psychedelics and the treatment for alcoholism.
Progress in neuro-psychopharmacology & biological psychiatry – December 20, 2024
Summary
A single dose of classic psychedelics can significantly reduce alcohol dependence, offering hope for those struggling with alcohol use disorder. These substances work by rewiring neural pathways in the brain, helping patients break free from destructive drinking patterns. Clinical trials show remarkable success rates, with many participants maintaining sobriety after treatment. Unlike conventional therapies, psychedelic-assisted treatment appears to address the root causes of dependence, rather than just managing symptoms.
Abstract
Alcohol is a harmful drug, and reducing its consumption is a significant challenge for users. Furthermore, alcohol dependence is often treatment-re...
Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review
Frontiers in Psychiatry – May 14, 2024
Summary
Profound subjective experiences from psychedelics like psilocybin and LSD are directly linked to specific changes in brain functional connectivity. A neuroscience review of 24 articles, selected from 492 in drug studies, reveals these substances profoundly alter consciousness and elevate mood. Psychology highlights decreased connectivity in brain networks involved in self-referential thought, alongside increased sensory processing. Such neurophysiological shifts offer a potential neural mechanism for reported mystical experiences, informing medicine's exploration of these compounds' therapeutic applications.
Abstract
Intense interest surrounds current research on psychedelics, particularly regarding their potential in treating mental health disorders. Various st...
Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.
Journal of racial and ethnic health disparities – June 01, 2025
Summary
Income and education levels significantly influence how different racial groups respond to psychedelics for mental health benefits. While white individuals show reduced psychological distress with psychedelic use, minorities experience diminished returns - even at higher socioeconomic levels. Notably, educated, high-income Asian users reported increased distress, highlighting how ethnicity and inequality shape therapeutic outcomes.
Abstract
Growing evidence suggests that the race and ethnic minority population may experience fewer protective effects of psychedelics on mental health. Th...
Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens
Dermatitis – April 18, 2024
Summary
Despite growing interest in hallucinogen and psychedelic substances for Medicine, their dermatologic side effects are poorly characterized. A review of 22 Psychedelics and Drug Studies on 40 patients revealed diverse dermatologic issues. Psilocybin, for instance, caused vesicular eruptions in four patients. Cannabis-related reactions included type I hypersensitivity in 21 cases. Other findings detailed acneiform eruptions from MDMA and ketamine hypersensitivity. Characterizing these dermatologic impacts is vital for patient care.
Abstract
Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly charac...
Solvent-free parallel artificial liquid membrane extraction for drugs of abuse in plasma samples using LC-MS/MS.
Analytica chimica acta – May 01, 2024
Summary
Scientists have developed a greener way to detect drugs in blood samples using natural essential oils instead of harmful chemical solvents. This breakthrough method uses a special extraction technique (PALME) combined with advanced testing to identify various substances, from traditional drugs to new synthetic compounds. The process proved highly accurate and efficient, detecting trace amounts while being more environmentally friendly than conventional methods.
Abstract
Parallel artificial liquid membrane extraction (PALME) is a 96-well plate setup variant of liquid-phase microextraction. Basic or acidic analytes a...
Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
American journal of therapeutics
Summary
Psychedelic medicines are reemerging as powerful tools for mental health treatment, with breakthrough results in treating depression, anxiety, and PTSD. Recent clinical trials show promising outcomes, particularly with MDMA for PTSD and psilocybin for depression. While remission rates match traditional antidepressants, these treatments offer new hope for those who haven't responded to conventional methods.
Abstract
Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsy...
Efficacy and Safety of Psychedelics in Treating Anxiety Disorders
Ochsner Journal – January 01, 2023
Summary
Psychedelics offer a promising new avenue for treating anxiety disorders. A review of 9 clinical trials, spanning various chemical compounds like LSD and psilocybin, revealed encouraging efficacy in reducing symptoms across conditions like generalized anxiety disorder and social anxiety. Patients experienced improved self-perception and social function, with therapeutic effects often lasting weeks. No severe adverse events were reported, suggesting these substances, explored within psychiatry and clinical psychology, could provide a safe and effective alternative in medicine for individuals with treatment-resistant anxiety, panic disorder, or agoraphobia.
Abstract
Background: Anxiety disorders are commonly diagnosed and cause substantial functional impairment. A mixture of pharmacologic and psychosocial treat...
Safety and tolerability of inhaled N,N-Dimethyltryptamine (BMND01 candidate): A phase I clinical trial.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology – March 01, 2024
Summary
Inhaled DMT shows promise as a rapid-acting psychedelic, with effects lasting just 10 minutes compared to hours for similar compounds. In this groundbreaking clinical trial, researchers tested different doses of N,N-Dimethyltryptamine in healthy volunteers, finding it both safe and well-tolerated. The dose-response study revealed positive mood effects and manageable physical responses, suggesting potential for treating mood disorders efficiently.
Abstract
Psychedelics are being increasingly examined for their therapeutic potential in mood disorders. While the acute effects of ayahuasca, psilocybin, a...
A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions.
Psychedelic medicine (New Rochelle, N.Y.) – December 01, 2023
Summary
Despite promising results in psychedelic-assisted therapy (PAT), a striking 82% of clinical trials fail to verify if treatments were delivered as intended. Current reporting practices in psychedelic research often omit crucial details about psychosocial interventions, including session duration, therapist qualifications, and treatment protocols. This gap affects treatment standardization and makes it harder to replicate successful outcomes across different settings.
Abstract
Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychos...
Drug–drug interactions involving classic psychedelics: A systematic review
Journal of Psychopharmacology – November 20, 2023
Summary
Remarkably, a review of 52 studies on classic hallucinogen interactions found few serious adverse drug events. This Pharmacology and Psychiatry review, spanning PsycINFO and MEDLINE, screened 7102 records for Psychedelics and Drug Studies. It examined how psychotropic drugs like Lysergic acid diethylamide, Psilocybin, and Mescaline, often from chemical synthesis and alkaloids, interact with recreational drugs, mood-affecting medications, and even dissociatives. Findings revealed varied effects, highlighting complex Neurotransmitter Receptor Influence on Behavior, vital for Medicine and Psychology.
Abstract
Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltry...
Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis
Journal of Psychoactive Drugs – November 15, 2023
Summary
Depression symptoms saw substantial relief from psychedelics, a meta-analysis of eighteen studies in clinical psychology reveals. Psilocybin therapy showed a large effect size (g = -1.92), while MDMA also significantly impacted depression (g = -0.71). These well-tolerated treatments, influencing neurotransmitter receptors, offer promising avenues for psychiatry and medicine, potentially aiding psychotherapists addressing anxiety and posttraumatic stress. While these chemical synthesis compounds are exciting for drug studies, current evidence has limitations like small sample sizes, highlighting the need for more robust investigation.
Abstract
There has been a resurgence in psychedelic research for managing psychiatric conditions in recent years. This study aimed to present a comprehensiv...
N, N-dimethyltryptamine forms oxygenated metabolites via CYP2D6 - an in vitro investigation.
Xenobiotica; the fate of foreign compounds in biological systems – December 01, 2023
Summary
The psychedelic compound DMT undergoes complex processing in the body through liver enzymes. Scientists discovered that a specific enzyme, CYP2D6, transforms DMT into new oxygen-containing compounds. Using human liver tissue samples, researchers found that this metabolic pathway works alongside the already-known MAO-A system. This finding advances our understanding of how the body processes DMT and may help explain individual differences in responses.
Abstract
N, N-dimethyltryptamine (DMT) is a psychedelic compound that has shown potential in the treatment of depression. Aside from the primary role of mon...
Cardiovascular safety of psychedelic medicine: current status and future directions
Pharmacological Reports – October 24, 2023
Summary
Psychedelics, powerful hallucinogens like psilocybin, Lysergic acid diethylamide, and mescaline, are re-emerging in medicine for psychiatry, improving mood and psychological well-being. Their pharmacology, involving serotonergic neurotransmitter receptor influence, is crucial. While clinical trials suggest relative cardiovascular safety in healthy populations for these five chemical synthesis and alkaloids, evidence is insufficient for microdoses or patients with heart conditions. Understanding the full cardiovascular impact of these drug studies, especially for intensive care medicine applications, is a vital area for pharmacology.
Abstract
Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychi...
A cane toad (Rhinella marina) N-methyltransferase converts primary indolethylamines to tertiary psychedelic amines.
The Journal of biological chemistry – October 01, 2023
Summary
Scientists have discovered that cane toads naturally produce enzymes that create psychedelic compounds similar to those found in magic mushrooms. The toad's N-methyltransferase enzyme efficiently converts simple compounds into complex psychedelic molecules that interact with brain serotonin receptors. This finding reveals nature's remarkable drug-making machinery and opens new paths for developing stable, therapeutic compounds.
Abstract
Psychedelic indolethylamines have emerged as potential medicines to treat several psychiatric pathologies. Natural sources of these compounds inclu...
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review
Journal of Psychopharmacology – July 01, 2023
Summary
Nearly all **clinical trials** on **psychedelics** face significant design challenges, raising concerns for **Medicine** and **Psychiatry**. A systematic review of 10 **randomized controlled trials** revealed that blinding was unsuccessful or unreported in every case, leading to 9 out of 10 trials being rated high risk of bias. These studies, identified via databases like **MEDLINE** and relevant to **Psychology** and **Clinical psychology**, often involved small, predominantly white, highly educated samples. Future rigorous **clinical trials** are crucial for advancing **Psychedelics and Drug Studies** and **Complementary and Alternative Medicine Studies** involving **chemical synthesis and alkaloids**.
Abstract
Background: The classical psychedelics, psilocybin, peyote, ayahuasca/ N,N-dimethyltryptamine, and lysergic acid diethylamide are considered promis...
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
European Neuropsychopharmacology – June 21, 2023
Summary
Psychedelic-assisted therapy offers compelling promise for severe Eating disorders like Anorexia nervosa and Bulimia nervosa. Preliminary data, from various studies and case reports, suggests potential in Psychiatry and Clinical Psychology for improving body image and cognitive flexibility. These novel Psychedelics and Drug Studies address common Comorbidity with Mood disorders and Anxiety. While data on Binge-eating disorder and Binge eating remains limited, mechanisms influencing Neurotransmitter Receptor Influence on Behavior offer new avenues. Psychotherapists in Medicine are exploring these treatments for challenging conditions.
Abstract
Eating disorders are serious illnesses showing high rates of mortality and comorbidity with other mental health problems. Psychedelic-assisted ther...
In vivo mapping of pharmacologically induced functional reorganization onto the human brain’s neurotransmitter landscape
Science Advances – June 14, 2023
Summary
The human brain's response to drugs reveals a profound link between molecular structure and behavior. Neuroscience shows diverse pharmacological agents, including 10 psychedelics and anesthetics, reorganize brain function by engaging multiple neurotransmitter systems. By mapping 19 neurotransmitter receptors and transporters, a clear influence on behavior emerged. This pharmacology insight has significant implications for Psychology and Medicine, informing drug studies and our understanding of brain disorders. Crucially, regional drug susceptibility mirrors vulnerability to structural alterations seen in conditions like those linked to Tryptophan imbalances.
Abstract
To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage the brain...
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics
Therapeutic Advances in Psychopharmacology – January 01, 2023
Summary
Many experience a "psychedelic afterglow" after using hallucinogens like psilocybin, often synthesized alkaloids. A review of 48 drug studies (1,774 participants) reveals this subacute period (up to a month) brings beneficial psychological changes. Individuals report reduced anxiety, improved mood, and wellbeing, offering new avenues for clinical psychology and psychiatry. While mild to severe adverse effects like headaches were observed, no serious adverse events occurred. Understanding these compounds' neurotransmitter receptor influence informs modern medicine.
Abstract
Background: Classic serotonergic psychedelics have anecdotally been reported to show a characteristic pattern of subacute effects that persist afte...
Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist's Training?
Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees – March 02, 2023
Summary
Should therapists personally experience psychedelics before guiding others? New findings challenge the common belief that first-hand psychedelic experience is essential for effective psychedelic therapy. While direct experience may offer insights, research suggests it's not crucial for successful therapeutic outcomes. Training programs can effectively prepare practitioners through other methods, making mandatory psychedelic use ethically questionable for therapist certification.
Abstract
Recent research offers good reason to think that various psychedelic drugs-including psilocybin, ayahuasca, ketamine, MDMA, and LSD-may have signif...
Psychedelics for Patients With Cancer: A Comprehensive Literature Review
Annals of Pharmacotherapy – January 12, 2023
Summary
For cancer patients battling **anxiety** and **depression**, psychedelics offer a compelling finding in **psychiatry**. Five randomized, **placebo**-controlled **drug studies** revealed substantial reductions on **rating scales** like the **Beck Depression Inventory**. These substances, often derived from **chemical synthesis and alkaloids**, offer a unique mechanism, presenting a novel therapeutic option in **medicine** and **clinical psychology**. Unlike traditional **psychology** treatments, benefits may extend 6-12 months from just a few sessions. While these **complementary and alternative medicine** approaches are still early, with small study sizes and noted blood pressure increases, they offer hope.
Abstract
Objective: To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer. Data Sources: PubMed search fro...
Rumors of Psychedelics, Psychotropics and Related Derivatives in Vachellia and Senegalia in Contrast with Verified Records in Australian Acacia.
Plants (Basel, Switzerland) – December 02, 2022
Summary
Australian Acacia trees contain unique psychoactive compounds like DMT and phenethylamine, unlike their African relatives. Chemical analysis reveals striking differences between these sister species: while Australian varieties produce powerful tryptamine compounds, African Vachellia and Senegalia show no evidence of these psychopharmacological substances, debunking popular myths about their similarity.
Abstract
There are almost 1000 species of Acacia sensu stricto in Australia, while the 44 species and 4 subspecies in southern Africa were taxonomically rev...
Psychedelic Drug Legislative Reform and Legalization in the US
JAMA Psychiatry – December 07, 2022
Summary
A majority of US states are projected to legalize psychedelics by 2034-2037, echoing Cannabis and Cannabinoid Research. Since 2019, 25 states considered 74 legislative initiatives and ballot measures. Most legislation (58%) proposes decriminalization, primarily for psilocybin (90% of bills). However, only 35% outline licensure or training for medical use. This rapid shift in public administration and medicine, informed by political science and Psychedelics and Drug Studies, highlights an urgent need for clear hallucinogen regulation and law reform.
Abstract
Importance Psychedelic drugs are becoming accessible in the US through a patchwork of state legislative reforms. This shift necessitates consensus ...
Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies
Addiction Biology – August 31, 2022
Summary
Classic psychedelics like psilocybin show promise in reducing alcohol consumption. A review of 27 Psychedelics and Drug Studies from the last two decades, including 20 Human studies, indicates these compounds could help. While some Human studies had methodological concerns, psilocybin emerged as a consistent potential candidate. Animal studies (7 included) were scarcer and less conclusive. These findings suggest a potential psychological and biological impact, warranting further rigorous investigation into these unique alkaloids for addiction treatment.
Abstract
Abstract Classic psychedelics refer to substances such as lysergic acid diethylamide (LSD), psilocybin, ayahuasca, and mescaline, which induce alte...
Default Mode Network Modulation by Psychedelics: A Systematic Review
The International Journal of Neuropsychopharmacology – October 21, 2022
Summary
Psychedelics like LSD and psilocybin profoundly alter brain activity, consistently disrupting the Default Mode Network (DMN), a key brain region for self-referencing and linked to various psychological conditions. This acute modulation of the DMN, crucial in neuroscience and drug studies, involves increased connectivity across brain networks. Understanding the chemical synthesis of these compounds and their psychological effects, perhaps alongside insights from nicotinic acetylcholine receptors studies and computational analyses, is vital to fully grasp their impact on brain function.
Abstract
Abstract Psychedelics are a unique class of drug that commonly produce vivid hallucinations as well as profound psychological and mystical experien...
Use of psychedelics in the Czech Republic: results of recent population surveys.
Central European journal of public health – September 01, 2022
Summary
Nearly one-third of Czech adults have experienced psychedelics or cannabis, with younger males being the predominant users. Recent population surveys reveal that 350,000-430,000 people have tried classical hallucinogens like LSD or psilocybin, while cannabis use is significantly higher at 2.1 million users. Current substance use patterns show similar demographic trends, highlighting shifting attitudes toward psychedelic substances.
Abstract
Different psychoactive substances are widely used in today's society. So far limited data are available on the use of psychedelics in the general p...
Towards an understanding of psychedelic-induced neuroplasticity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2023
Summary
Psychedelics like LSD and psilocybin can rewire the brain's neural connections, particularly in areas controlling mood and memory. These substances trigger rapid growth of new neural connections and enhance brain plasticity, especially in the prefrontal cortex and hippocampus. This helps explain why a single treatment can lead to lasting positive changes in depression and anxiety that persist for months.
Abstract
Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage ayahuasca, show some potential to treat depression, anxiety, and add...
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology – June 15, 2025
Summary
Psychedelics are revolutionizing Psychiatry. Psilocybin and MDMA, powerful hallucinogens, show promise as rapid antidepressants and anxiolytics in Psychology and Neuroscience. These Psychedelics and Drug Studies highlight their ability to target monoamine neurotransmitter systems, specifically 5-HT2A receptors, influencing behavior. They correct neural network defects in Major depressive disorder and Anxiety, linked to altered brain tryptophan metabolism. Psilocybin received FDA breakthrough status for depression, while MDMA for PTSD was recently rejected. This offers new hope for severe mental health conditions.
Abstract
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin...
Psychedelics in the treatment of unipolar and bipolar depression
International Journal of Bipolar Disorders – July 05, 2022
Summary
Psilocybin shows promising efficacy in initial randomized trials for unipolar depression, signaling a renaissance in psychiatry. This hallucinogen, alongside lysergic acid diethylamide and mescaline, influences mood by affecting neurotransmitter receptors. While classic psychedelics risk inducing mania, a concern for bipolar disorder, ketamine's enantiomer is already approved for treatment-resistant depression. Clinical psychology explores psychedelic-assisted psychotherapy. Future psychopharmacology and drug studies, requiring larger sample sizes and careful chemical synthesis of alkaloids, will determine their broader role for psychotherapists in psychiatry.
Abstract
Abstract This is a narrative review about the role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression. Si...
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
Frontiers in Psychiatry – July 12, 2022
Summary
Compelling findings for **Psychology**: mystical experiences significantly reduce **distress** and **anxiety**. Ten of twelve reviews on **psychedelics** like psilocybin (derived from **chemical synthesis and alkaloids**) confirm a strong link between these profound experiences and symptom reduction. This offers promising avenues for **Clinical psychology**, **Psychiatry**, and **Psychotherapists**, illustrating how these substances, through **neurotransmitter receptor influence**, affect behavior. While impactful, many analyses had small sample sizes, suggesting the need for broader investigation in **Drug Studies**.
Abstract
The mystical experience is a potential psychological mechanism to influence outcome in psychedelic therapy. It includes features such as oceanic bo...
Psychedelic Therapy: A Primer for Primary Care Clinicians – Part I. Historical Perspective and Overview
OpenAlex – December 26, 2023
Summary
MDMA shows striking promise, proving superior to existing treatments for PTSD in two completed Phase III clinical trials. This marks a new frontier in Psychiatry and Medicine. While a Psilocybin clinical trial is underway, larger studies (over 100 participants) suggest it may not surpass current antidepressants for depression. The pharmacology of various psychedelics, including Lysergic acid diethylamide and other hallucinogens, derived from chemical synthesis and alkaloids, offers significant hope for anxiety, influencing behavior via neurotransmitter receptors.
Abstract
Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and ot...
On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.
OpenAlex – May 23, 2024
Summary
Potent hallucinogens like psilocybin offer rapid, long-lasting antidepressant and anxiolytic effects for major depressive disorder and anxiety, often after just one or two administrations. Neuroscience and psychiatry reveal these psychedelics modulate the serotonin system, crucial for brain function and implicated in tryptophan-related disorders. Their chemical synthesis yields alkaloids showing promise in drug studies, achieving FDA breakthrough status for conditions involving neuroinflammation and neuroplasticity, revolutionizing psychology's approach to mental health.
Abstract
There is controversy about a causal role of serotonin (5-HT) in depression, some arguing that there is no proof for impaired brain 5-HT function in...
Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress
Psychedelic Medicine – April 22, 2025
Summary
Psychedelic use, including psilocybin and LSD, is linked to reduced psychological distress stemming from mental health stigma, according to an analysis of 458,372 individuals. This finding, relevant to clinical psychology, suggests potential benefits for mental well-being. However, the impact varies significantly; White men show stronger associations between lifetime psychedelic use and lower distress from stigma. For other groups, including women and individuals of different race/ethnicity, these associations are less pronounced. The influence of these substances on neurotransmitter receptors, often involving tryptophan-derived compounds, may alter social psychology related to stigma, but benefits are not universal.
Abstract
Objective: Prior research has found an association between psychedelic use and reduced stigma attached to mental illness. However, whether psychede...
Serotonergic psychedelics for depression: A comprehensive overview.
International review of neurobiology – January 01, 2025
Summary
Imagine a single treatment rapidly easing severe depression. Recent insights from clinical trials show certain psychedelics, like psilocybin, offer profound and sustained relief for major depressive disorder (MDD) and treatment-resistant depression (TRD). These powerful compounds demonstrate antidepressant effects comparable to conventional therapies, presenting a promising new frontier in addressing challenging forms of depression.
Abstract
Depressive disorders continue to pose a major clinical challenge worldwide, particularly given the high prevalence and increasing number of treatme...
Effects of psychedelics on human oscillatory brain activity.
International review of neurobiology – January 01, 2025
Summary
Psychedelic compounds profoundly reorganize brain activity. Using EEG and MEG, researchers investigated how these substances alter neural oscillations. A key finding was a consistent decrease in alpha power, indicating reduced inhibitory control, alongside a significant increase in brain signal complexity. This suggests altered functional connectivity, potentially reversing typical top-down processing. These objective EEG markers offer valuable insights into the unique psychedelic experience and its therapeutic potential.
Abstract
This chapter reviews the effects of classic psychedelics on human oscillatory brain activity, as measured by resting-state electroencephalography (...
Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.
CNS drugs – July 10, 2025
Summary
Remarkably, psychedelics have been explored for alcohol use disorder since the 1950s. A comprehensive review of foundational studies reveals promising results from observational research. While controlled trials show varied outcomes due to diverse methods, potential mechanisms—from brain changes to social connection—are being actively investigated, highlighting their positive role in addressing alcohol challenges.
Abstract
Psychedelics have been studied since the 1950s as a potential treatment for alcohol use disorder (AUD), with over a dozen clinical trials of lyserg...
A review of psychedelics trials completed in depression, informed by European regulatory perspectives.
Neuroscience applied.. – January 01, 2025
Summary
As European regulators prepare for new treatments, eight completed clinical trials reveal key insights into using psychedelics for depression. These clinical trials, testing various psychedelics, highlight the importance of aligning their design with emerging regulatory guidance. This collaboration is crucial for successful medicines development, paving the way for innovative depression treatments.
Abstract
There is a growing body of clinical research on the therapeutic potential of psychedelics for the treatment of mental health disorders, notably dep...
OAV and 5D-ASC for Brazilian Portuguese: A validation and adaptation study.
Journal of psychopharmacology (Oxford, England) – June 28, 2025
Summary
Understanding the profound subjective experiences induced by Psychedelics is crucial. New research successfully adapted and validated key psychometrics, like the OAV, for use in Brazil, specifically to measure altered states of consciousness. Through robust methods, including expert reviews and a large online survey of 3762 individuals, the scales demonstrated strong reliability and validity. This confirms their effectiveness in capturing diverse psychedelic experiences, highlighting cultural nuances.
Abstract
This study aimed to validate and culturally adapt the Altered States of Consciousness Rating Scale (OAV) and Five Dimensional-Altered States of Con...
Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics
Frontiers in Psychiatry – February 11, 2020
Summary
A large population survey reveals classic tryptamines are linked to significantly reduced psychological distress and suicidal thoughts. This suggests strong potential for psychedelic-assisted therapy, particularly for mental health outcomes. While lysergamides showed no clear link, novel phenethylamines were associated with increased suicidal ideation, highlighting the specific promise of classic tryptamines.
Abstract
IntroductionThe majority of contemporary psychedelic research has focused on ayahuasca, lysergic acid diethylamide, and psilocybin, though there ar...
Treatment and therapy of mental health conditions in the Global South using psychedelics: A scoping review and narrative synthesis
Journal of Psychedelic Studies – June 21, 2024
Summary
Traditional plant medicines show renewed promise for mental health. A review explored psychedelic treatment for mental health conditions in the Global South. It found these approaches are feasible and demonstrate promising efficacy for issues like depression. Importantly, they offer excellent safety with no serious side effects and prove cost-effective, providing a vital new option for communities with unmet needs.
Abstract
AbstractBackground and aimsPsychedelics show promise for treatment of mental health conditions (MHCs). But there is relatively little research on i...
Psychoactive Substances of Natural Origin: Toxicological Aspects, Therapeutic Properties and Analysis in Biological Samples.
Molecules (Basel, Switzerland) – March 05, 2021
Summary
Many natural plants possess powerful compounds with diverse psychoactive effects. A comprehensive review investigated twelve such nps of natural origin, delving into their historical traditional uses and promising therapeutic properties. It also meticulously detailed their toxicological aspects and the advanced analytical methodologies essential for their detection in biological samples. The work illuminates the complex balance of benefits and risks these unique substances present.
Abstract
The consumption of new psychoactive substances (NPSs) has been increasing, and this problem affects several countries worldwide. There is a class o...
Hallucinogens and Their Therapeutic Use: A Literature Review.
Journal of psychiatric practice – September 01, 2019
Summary
A fascinating trend reveals renewed interest in hallucinogens for mental health. A review of existing literature explored their psychotherapeutic uses in psychiatric disorders. It found substances like psilocybin, MDMA, and ketamine have been evaluated for conditions including depression and substance use disorders. Most findings demonstrated significant improvement, underscoring their promising therapeutic potential.
Abstract
The exploration of possible therapeutic benefits of hallucinogenic substances has undergone a revitalization in the past decade. This literature re...
Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor.
Psychopharmacology – June 01, 2012
Summary
How the body processes natural compounds dictates their lasting impact. Scientists explored if the unique, prolonged effects of a psychoactive substance, observed when its breakdown is slowed, are due to extended action. Using a specially modified, metabolism-resistant version of the compound in rats, they successfully replicated the full biphasic behavioral pattern: an initial calming followed by increased activity. This shows that reduced breakdown enables the compound to engage brain receptors longer, providing a valuable tool for studying such compounds.
Abstract
Ayahuasca is a psychoactive tea prepared from a combination of plants that contain a hallucinogenic tryptamine and monoamine oxidase inhibitors (MA...